Considerations in the Design of Non-Clinical Development Programmes to Support Non-Viral Genetically Modified Mesenchymal Stromal Cell Therapies
- PMID: 34199356
- PMCID: PMC8228211
- DOI: 10.3390/pharmaceutics13060823
Considerations in the Design of Non-Clinical Development Programmes to Support Non-Viral Genetically Modified Mesenchymal Stromal Cell Therapies
Abstract
Due to their immune suppressive pharmacology, regenerative capacity, and immune privileged status, mesenchymal stromal cells (MSCs) are an attractive cell type to treat a variety of diseases. Genetically engineered MSCs are currently in non-clinical and clinical development for a wide range of applications including the delivery of pro-drugs and therapeutic proteins or modified to enhance their regenerative potential. Unmodified MSCs have been shown to have good safety profiles in clinical development. The introduction of exogenous transgenes introduces possible additional risks that need to be assessed in non-clinical studies prior to initiating clinical studies. The use of ex vivo non-viral genetic modification approaches potentially reduces the risks associated with viral vector transfection approaches, including the potential for cell transformation. This review provides an overview of the regulatory-compliant non-clinical proof-of-concept and safety studies required to take MSC-based gene therapy products from the bench to the clinic.
Keywords: MSC; cell therapy; gene therapy; genetically modified; mesenchymal stem cells; mesenchymal stromal cells; non-clinical strategy; non-viral approaches; preclinical studies; regulatory requirements.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Minicircle microporation-based non-viral gene delivery improved the targeting of mesenchymal stem cells to an injury site.Biomaterials. 2016 Sep;101:310-20. doi: 10.1016/j.biomaterials.2016.05.057. Epub 2016 Jun 2. Biomaterials. 2016. PMID: 27315214
-
Regulatory-compliant conditions during cell product manufacturing enhance in vitro immunomodulatory properties of infrapatellar fat pad-derived mesenchymal stem/stromal cells.Cytotherapy. 2020 Nov;22(11):677-689. doi: 10.1016/j.jcyt.2020.06.007. Epub 2020 Jul 26. Cytotherapy. 2020. PMID: 32723596
-
Genetic Engineering as a Strategy to Improve the Therapeutic Efficacy of Mesenchymal Stem/Stromal Cells in Regenerative Medicine.Front Cell Dev Biol. 2020 Aug 21;8:737. doi: 10.3389/fcell.2020.00737. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32974331 Free PMC article. Review.
-
Safety Profile of Good Manufacturing Practice Manufactured Interferon γ-Primed Mesenchymal Stem/Stromal Cells for Clinical Trials.Stem Cells Transl Med. 2017 Oct;6(10):1868-1879. doi: 10.1002/sctm.16-0485. Epub 2017 Sep 9. Stem Cells Transl Med. 2017. PMID: 28887912 Free PMC article.
-
Mesenchymal Stromal/Stem Cells: A New Era in the Cell-Based Targeted Gene Therapy of Cancer.Front Immunol. 2017 Dec 18;8:1770. doi: 10.3389/fimmu.2017.01770. eCollection 2017. Front Immunol. 2017. PMID: 29326689 Free PMC article. Review.
Cited by
-
Scalable manufacturing of gene-modified human mesenchymal stromal cells with microcarriers in spinner flasks.Appl Microbiol Biotechnol. 2023 Sep;107(18):5669-5685. doi: 10.1007/s00253-023-12634-w. Epub 2023 Jul 20. Appl Microbiol Biotechnol. 2023. PMID: 37470820 Free PMC article.
References
-
- Viswanathan S., Shi Y., Galipeau J., Krampera M., Leblanc K., Martin I., Nolta J., Phinney D.G., Sensebe L. Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21:1019–1024. - PubMed
Publication types
LinkOut - more resources
Full Text Sources